AG真人官方

Liquidia Corporation (LQDA) 鈥� Form 4 filing dated 15-Jul-2025 details two insider transactions by Chief Commercial Officer Scott Moomaw.

• 07-11-2025: 3,107 common shares were acquired through the conversion of vested performance stock units (Code M). This increased Moomaw鈥檚 direct holdings to 228,028 shares.
• 07-14-2025: 4,797 shares were sold at $14.28 per share (Code S) under a pre-arranged Rule 10b5-1 plan to cover tax obligations arising from recent RSU/PSU settlements. Post-sale, the executive directly owns 223,231 shares.

The filing also discloses a sizeable pipeline of unvested equity: 31,249 RSUs from a 2023 grant, 31,077 RSUs from a 2024 grant, and 69,729 RSUs granted in 2025. In addition, 11,002 shares were accumulated via the company鈥檚 2020 ESPP.

No cash proceeds were reported for the acquisition; the sale generated roughly $68.5 k in gross proceeds. The net effect is a marginal reduction of 1,690 shares (<1% of the executive鈥檚 stake), suggesting a routine tax-related transaction rather than a directional view on Liquidia鈥檚 prospects.

Dimensional Fund Advisors LP (DFA) has filed a Schedule 13G indicating that, as of 30 June 2025, it beneficially owns 1,572,330 shares of Boston Omaha Corp ("BOC"), representing 5.1 % of the company鈥檚 outstanding common stock. The institutional investor reports sole voting power over 1,540,879 shares and sole dispositive power over the full 1,572,330-share position, with no shared voting or dispositive authority.

DFA, a Delaware limited partnership and SEC-registered investment adviser, explains that the shares are held across multiple mutual funds, commingled trusts and separate accounts for which it or its subsidiaries act as adviser or sub-adviser. While DFA may exercise voting and investment discretion, it expressly disclaims beneficial ownership in excess of the requirements of Section 13(d).

Crossing the 5 % ownership threshold triggers this disclosure and signals a modest increase in institutional ownership in BOC. Because DFA is predominantly a passive, quantitative manager, the filing does not suggest an activist agenda or an intention to influence control. Nevertheless, additional institutional sponsorship can enhance liquidity, broaden research coverage and potentially support the share price through index-related demand.

Key numeric details

• Date of event: 30 June 2025
• Shares owned: 1,572,330
• Percent of class: 5.1 %
• Sole voting power: 1,540,879
• Sole dispositive power: 1,572,330

Overall, the Schedule 13G is an informative but routine ownership disclosure that underscores growing passive interest in Boston Omaha without materially altering corporate governance or near-term strategy.

Williams-Sonoma, Inc. (WSM) has filed a Form 144 indicating the planned sale of insider shares under Rule 144.

• Shares to be sold: 75,000 common shares
• Estimated value: US$12,610,695.50 (based on the market price at filing)
• Broker: Merrill, 555 California St., San Francisco, CA 94103
• Planned sale date: 15 July 2025 on the NYSE
• Shares outstanding: 122,998,061, so the proposed sale equals roughly 0.06 % of shares outstanding
• Source of shares: 165,000 RSUs acquired on 16 April 2024 for cash consideration
• Recent insider activity: Laura Alber sold 30,000 shares on 29 May 2025 for gross proceeds of US$4,929,685.47

The filing provides notice that the seller (not expressly named for the current transaction, but Laura Alber is listed as the most recent seller) does not possess undisclosed material adverse information, a standard representation under Rule 144. No financial performance data or earnings metrics are included; the document is limited to insider sale disclosures.

UBS AG is offering Trigger Autocallable Contingent Yield Notes (unsubordinated, unsecured debt) linked to Regeneron Pharmaceuticals, Inc. common stock. The notes have an expected 30-month term, issuing 16 Jul 2025 and maturing 18 Jan 2028, with quarterly observation dates. Investors receive a fixed contingent coupon of 9.01 %鈥�9.87 % p.a. ($0.2253鈥�$0.2468 per $10 note) only if Regeneron鈥檚 closing price on an observation date is at least 60 % of its initial level (the 鈥渃oupon barrier鈥�).

Automatic call: The notes are redeemed early at par plus the quarterly coupon if Regeneron closes at or above its initial level on any observation date before final valuation. Early call may occur as soon as the first quarter, creating reinvestment risk.

Principal repayment: 鈥� If not called and the final level is 鈮� the 60 % downside threshold, investors receive full principal.
鈥� If the final level is < the downside threshold, repayment equals $10 脳 (1 + underlying return), resulting in a dollar-for-dollar loss beyond 40 % decline; maximum loss is 100 % of principal.

Key economics

• Issue price: $10; minimum purchase 100 notes ($1,000).
• Estimated initial value: $9.47鈥�$9.72 (reflects underwriting discount, hedging and funding costs).
• Underwriting discount: $0.175 per note (1.75 %).

Risk highlights

• Market risk identical to holding Regeneron below the 60 % threshold at maturity.
• No participation in upside beyond fixed coupons; dividends on Regeneron are foregone.
• Credit risk of UBS: all payments depend on UBS AG鈥檚 ability to pay; notes are not insured.
• Liquidity risk: notes will not be listed; secondary market, if any, may be illiquid and priced below issue price.
• Conflicts of interest: UBS entities act as issuer, distributor, calculation agent and market maker.
• Tax treatment uncertain; UBS treats notes as prepaid derivatives with ordinary-income coupons.

Investor suitability: suitable only for investors who (1) can tolerate potential total loss, (2) believe Regeneron will remain above 60 % of its initial level, (3) are comfortable with UBS credit exposure, and (4) accept limited liquidity and capped return.

Gilead Sciences, Inc. (GILD) filed a Form 4 on 07/01/2025 reporting that Chairman & CEO Daniel P. O鈥橠ay executed two open-market sales of the company鈥檚 common stock on 06/30/2025.

• Shares sold: 9,400 shares at a weighted-average price of $110.4038 and 600 shares at $111.1467, for a total of 10,000 shares.
• Remaining holdings: O鈥橠ay now directly owns 615,725 shares, down from 625,725, a reduction of roughly 1.6%.
• Trading plan: Transactions were carried out under a Rule 10b5-1 trading plan adopted on 02/28/2025, indicating pre-scheduled, automated execution.
• Price ranges: The first tranche was executed between $110.03 and $111.00; the second between $111.03 and $111.17. Detailed breakdowns are available upon request.
• No derivative securities or additional insider transactions were reported in this filing.

The filing signals continued, but limited, share disposition by the CEO within a structured trading program. Because the sale represents a small percentage of his total ownership and was executed under a 10b5-1 plan, the market impact is likely modest and largely informational rather than strategic.

Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.

The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite鈥檚 market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite鈥檚 fundamentals; it solely discloses the insider鈥檚 intent to sell under Rule 144.